Celltech and American Cyanamid
Lederle parent is Celltech's partner in a cancer research agreement. Lederle will shepherd through clinical trials, FDA review, and marketing any products developed by the British research firm. Celltech will receive $7.5 mil. initially for two years "to develop a new approach to antibody cancer imaging and therapy using" second generation "monoclonal antibodies," Celltech announced ("The Pink Sheet" April 14, In Brief).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.